Background
Background
Kidney cancer is one of the most common cancers in both men and women, with ccRCC being the most frequent and aggressive subtype [1, 2] . Biallelic inactivation of the VHL gene caused by chromosome 3p loss, mutation or hypermethylation is observed in over 80% of ccRCC [3, 4] . The VHL protein, pVHL, functions as the recognition subunit of an E3 ubiquitin ligase complex. The canonical role of pVHL is to promote the degradation of the hypoxia-inducible transcription factors α (HIF1α, HIF2α, and HIF3α, collectively HIFα) through oxygen-sensitive ubiquitin-mediated proteolysis. Loss of function of pVHL results in the constitutive stabilization of HIFα, which promotes inappropriate expression of downstream genes involved in angiogenesis, metabolism, and proliferation and thus contributes to tumorigenesis [5] . In addition to its role in HIFα regulation, pVHL has been implicated in a variety of HIF-independent processes including extracellular matrix regulation [6] , cilium formation [7] [8] [9] [10] , microtubule stabilization [11] , protein synthesis [12] , apoptosis [13] , mitosis [14, 15] , cell senescence [16, 17] and DNA repair [18] . With increased understanding of pVHL function and ccRCC pathogenesis, a number of targeted therapies have been developed, including antiangiogenic agents and mTOR inhibitors [19] . However, the development of drug-induced resistance and dismal prognosis of patients with metastatic diseases has heightened the need for novel therapeutics for ccRCC management.
Since inactivation of VHL is a signature lesion in almost all ccRCC, it provides the opportunity to discover VHL-specific genetic vulnerabilities in tumor cells that can be exploited for discovery of new therapeutic targets. Since it is challenging to pharmacologically restore an inactivated tumor suppressor gene, one approach would be to identify genes that are synthetically lethal (SL) with VHL. Two genes are considered to be SL if mutations of both genes lead to cellular or organismal death but the mutation of either gene alone enables viability [20, 21] . Therapeutic strategies based on synthetic lethality may provide drug targets when the cancer-causing genes cannot readily be targeted and enable selective killing of cancer cells while sparing normal cells [22, 23] . To this end, several VHL SL partners have been discovered using multiple approaches including hypothesis-driven mechanistic studies, compound screening and small-scale short hairpin RNA screening [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . However, systematic identification of VHL SL genes at a genome-wide scale has not been reported to date.
Clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) has recently emerged as a powerful and versatile tool for mammalian genome engineering [37] [38] [39] [40] [41] [42] . The site-specific DNA double-strand breaks induced by CRISPR-Cas9 are mainly repaired by non-homologous end joining, which often causes gene disruption by frameshift mutation. Given its high efficiency and scalability, CRISPRCas9 has been quickly adopted in genome-wide loss-of-function genetic screens to identify common and context-dependent essential genes in mammalian cells [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] .
Here, we developed a strategy to identify VHL SL genes by performing parallel CRISPRCas9 screens in isogenic pairs of cancer cell lines that are genetically identical except for the VHL status. Through genome-wide CRISPR screening followed by rigorous validation screening and transcriptome profiling, we identified novel biological processes that are SL with VHL, including selenocysteine biosynthesis and DNA damage response pathway. We validated screening hits using genetic and pharmacological approaches and elucidated underlying molecular mechanisms. We also discovered a subset of the VHL SL genes had elevated expression in VHL-deficient cell lines and in primary ccRCC tumor tissues, which correlated with poor overall survival of affected patients. Our work uncovers paths to novel therapeutic strategies for ccRCC and provides a rich resource for future investigation of the function of the VHL tumor suppressor protein. Similar approaches could potentially be applied to identify SL partners of other oncogenic drivers such as PI3K pathway alterations, MYC activation, TP53 inactivation and RAS oncogenes.
Results

Generation of isogenic VHL ccRCC cell line pairs
To facilitate the discovery of genetic vulnerabilities dependent on VHL loss, we took an unbiased genome-wide CRISPR screening approach using isogenic pairs of ccRCC cell lines that only differ in the VHL gene ( Table S1 ,S2). Compared to VHL -/-cells, VHL + cells showed upregulation of the genes in Krebs cycle and p53 signaling pathway, and downregulation of those associated with hypoxia and NF-kB signaling (Supplemental Fig. S2 ). These observations are consistent with the established role of pVHL in both normal cells and ccRCC tumors [13, [54] [55] [56] [57] [58] . In agreement with previous findings [59 -61] , VHL status did not affect the rate of cell proliferation under normal cell culture conditions (Supplemental Fig. S3 ). Overall, we created two pairs of Cas9-proficient VHL -/-and VHL + isogenic cell lines, which recapitulated key aspects of known ccRCC biology and served as cellular models for VHL SL CRISPR screens.
Genome-wide CRISPR-Cas9 screens in isogenic VHL ccRCC cell lines
We subsequently proceeded to perform CRISPR screens in the two pairs of isogenic ccRCC cell lines using a genome-wide lentiviral library [62] . (Fig. 3D ).
The human selenoproteome consists of 25 selenoproteins that are expressed in various tissues and organs [70] . Although the role of selenoproteins in tumorigenesis remains elusive, certain seleno-enzymes such as glutathione peroxidases and thioredoxin reductases are known to regulate cellular redox and protect cells from reactive oxygen species (ROS) [71, 72] . As pVHL plays important roles in the cellular response to changing oxygen levels and redox potentials [17, 73, 74] , it can be hypothesized that Table S11 ). RNA-seq analysis showed that the screening hits associated with DDR signaling were highly upregulated in VHL -/-versus VHL + cells (Supplemental Fig. S11 and Fig. 4B ,C). Taken together, our data suggest that pVHL loss induces DNA damage-related stress, thus rendering VHL -/-cells more reliant on DDR components for survival than VHL + cells.
To explore the clinical relevance of our discovery, we analyzed The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma (TCGA-KIRC) data set, which includes transcriptome profiling of 537 primary tumors and 72 normal solid tissues correlated with clinical outcome of ccRCC patients [65] . Three of the validated screening hits, CDK1, CHEK1 and TOP2A, were overexpressed in ccRCC ( Fig. 4D ) and associated with poor prognosis (Fig. 4E ). Evaluation of all the DDR genes that we found to be SL with VHL showed that 52 DDR genes were significantly upregulated in primary ccRCC tumors (Fig. 4B,F and Supplemental Table S12 ). In addition, a gene expression signature derived from these 52 genes serves as a robust biomarker for predicting overall survival of ccRCC patients (Fig. 4G ). In contrast, the gene expression signature of 52 randomly selected genes that are overexpressed in primary tumors was not associated with patient outcome (Fig. 4H ). These results indicate that the screening hits we identified here represent bona fide VHL SL interactors in primary human tumors and serve as potential drug targets to develop effective treatment strategies.
Discussion
Genome genotypes, expression profiles, and tissue and cellular origins. Genotype-specific lethality or SL is a therapeutic strategy based on the observations that over the course of pathogenesis, cancer cells acquire a few key driver mutations and as a result become dependent on other genes for survival [80] [81] [82] . This strategy has been successfully employed in the development of PARP inhibitors as a novel therapeutic approach to certain cancers with BRCA mutations [83, 84] . VHL mutations present a promising opportunity to discover SL targets for ccRCC as they are found in up to 92% of the disease [4] . We hoped to reduce the number of cell lines needed to reveal SL genes by screening isogenic pairs of cell lines that are genetically identical except for a key tumor driver gene. To demonstrate this advantage, we utilized two VHL-null ccRCC cell lines and reconstituted them with a wild-type copy of the gene to create isogenic pairs of VHLdeficient and -proficient cell lines (Fig. 1A ). Our screening data have shown that over one thousand genes are essential for the parental VHL-null ccRCC cell lines and they included more than two thirds of the "common essential" genes ( ccRCC represents a serious unmet medical challenge as the prognosis for advanced patients remains poor. Better understanding of molecular genetic mechanisms that drive ccRCC could therefore lead to the development of efficient therapeutic strategies for this devastating disease. Our screens have uncovered multiple cellular signaling networks that are SL with VHL. Of these, mTOR signaling is one of the well-established therapeutic targets for ccRCC. However, two molecular networks, selenocysteine biosynthetic pathway and DDR pathway, have not previously been linked to this disease (Fig. 2E) . Here, we show that five of the six selenocysteine biosynthetic pathway genes are SL with VHL (Fig. 3) [85] . Our discovery suggests that modulating unique redox regulatory mechanisms such as selenocysteine biosynthesis might provide a selective anticancer strategy.
Another major class of VHL SL genes belongs to DDR pathways (Fig. 4) . Conventional chemotherapeutics like DNA alkylating agents kill cancer cells through mitotic catastrophe caused by cumulative DNA damage. However, use of these drugs has undesirable side effects because of a narrow therapeutic index. Our results show novel targets in DDR pathways with potentially wider therapeutic index. In addition to their potential as therapeutic targets, VHL SL DDR pathway genes showed strong predictive power for kidney cancer prognosis, especially when combined with mRNA profiling data (Fig. 4G ). This suggests the importance of functional information provided by CRISPR screens in kidney cancer prognosis. Whereas the precise molecular basis of the SL interaction between VHL and selenocysteine biosynthesis or DDR will require further investigation, these studies suggest novel mechanisms of interplay between multiple cancer-relevant cellular processes. Interestingly, these two newly discovered VHL SL mechanisms may also be connected, as elevated ROS can cause DNA damage [85] .
Although we focused on selenocysteine biosynthesis and DDR in this study, our screening results suggest additional VHL SL genes that merit further exploration. For example, protein ubiquitination pathway genes were significantly enriched among screening hits (Fig. 2E ). As proteasome inhibitors are currently being used in clinic for cancer treatment [86] , it would be interesting to investigate the efficacy of proteasome inhibitors in ccRCC. In another example, our screens identified a number of VHL SL genes associated with major metabolic pathways, including pyrimidine biosynthesis (DTYMK and RRM2), glycolysis (TPI1 and PKM), fatty acid metabolism (HSD17B10), pentose phosphate pathway (RPE), and cholesterol biosynthesis (GGPS1). These observations reinforce already established roles of metabolic reprogramming in kidney cancers [87] . Finally, considering the increasing number of malignancies involving VHL inactivation, including hemangioblastoma, pheochromocytoma and pancreatic neuroendocrine tumors [88, 89] , our study provides a framework for understanding molecular pathogenesis of VHL inactivation in additional cancer types.
Conclusions
In this study, we applied a hypothesis-free strategy to identify VHL SL interactors based on CRISPR-mediated genetic screening. We performed parallel CRISPR screens in isogenic cell lines sharing the same genetic makeup except for VHL status. Through genome-wide screens followed by deeper focused screens, we confirmed a well-known role of mTOR signaling and uncovered novel biological processes, including selenocysteine biosynthesis and DNA damage response, which are SL with VHL. Our CRISPR and RNA-seq datasets provide a rich resource for future investigation of the function of pVHL. Our approach could potentially be employed to unveil SL partners with other oncogenic drivers. Imaging System (LI-COR Biosciences).
RNA extraction and sequencing
Total RNA was extracted from 1-2 million cells using RNeasy Mini Kit (QIAGEN) using 
RNA expression analysis
RNA-seq analysis was carried out by aligning Illumina reads using STAR aligner [90] against human reference sequence (Ensembl Release 84). Expression level is estimated using FeatureCount [91] . Differential Expression analysis was carried out using DESeq2 R Bioconductor package [92] . Ranked gene lists were further analyzed by gene set enrichment analysis (GSEA) [93] .
EGFP disruption assay for Cas9 activity
Parental cells and Cas9-expressing cells were infected with a lentivirus carrying an EGFP-2A-puroR cassette and a sgRNA targeting EGFP by spinfection in 12-well plates at 1000 xg for 2 hr, in the presence of 8 µg/µL polybrene. Plates were then returned to 37 °C with 5% CO 2 . Cells were incubated overnight and then selected by puromycin (3 μ g/mL, Sigma-Aldrich). Cells were passaged and cultured under puromycin selection for at least 5 days before flow cytometry analysis using an LSRFortessa X20 instrument (BD Biosciences). between all samples was done using the "median ratio method" [94] implemented in the DESeq2 R Bioconductor package. Hit selection for the primary screen was carried out using Student t test for the "second best" method and MAGeCK [64] .
Genome-wide CRISPR synthetic lethality screens
>140 million 786-O-VHL
Secondary CRISPR screening
The secondary screening procedure was similar to genome-wide CRISPR screens with 
Gene ontology and pathway analysis
Gene ontology and pathway analysis was performed with Ingenuity Pathway Analysis (QIAGEN) on the 350 VHL synthetic lethal genes. Fisher's exact test was used to calculate a P value determining the probability that each biological function assigned to that data set was due to chance alone.
Cell proliferation assay for target validation
Cas9-expressing cells were infected with lentiviral constructs carrying mCherry and gene-targeting sgRNAs at high MOI by spinfection in 12-well plates at 1000 xg for 2 hr, in the presence of 8 µg/µL polybrene. Plates were then returned to 37 °C with 5% CO 2 .
Cells were incubated 48 hr and then trypsinized. Cells were then counted and seeded into 96-well plates. The plates were scanned by Incucyte ZOOM live cell imaging system (Essen Bioscience) every 12 hr. Proliferation of the infected cells was analyzed under red fluorescence automated imaging mode.
Competitive growth assay
Cas9-expressing cells were transduced with a lentivirus expressing mCherry and a gene-specific sgRNA at high MOI by spinfection in 12-well plates at 1000 xg for 2 hr, in the presence of 8 µg/µL polybrene. Plates were then returned to 37 °C with 5% CO 2 
Study on the effects of selenium depletion
The 
Cell viability assay for drug treatment
Cells were plated into black-walled 384-well plates (Corning) together with mimethyl sulfoxide or chemicals at various concentrations (3-fold dilution). Cell viability was quantified using Cell Titer-Glo Luminescent Cell Viability Assay (Promega) according manufacturer's instruction.
Primary tumor sample analysis and survival analysis
We used TCGA data sets of gene expression data (Illumina Hiseq RNA sequencing data) for kidney renal clear cell carcinoma samples and patients' clinical record (http://gdac.broadinstitute.org/). Differential Expression analysis was carried out using DESeq2 R Bioconductor package [92] in order to identify the genes that are overexpressed in primary tumors versus normal tissues, using a cutoff of P value < 0.05.
For the survival analysis, we use 'time-to-event' univariate Cox proportional hazard model on each gene to determine the impact. Kaplan-Meier plots also show the comparisons between curves by log rank test. General survival analysis over the gene list utilized median z score of gene expressions among "Tumor" and "Normal" groups.
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